07/31/2023 ADOCIA Announces Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Icon check
07/27/2023 ADOCIA Announces the Availability of a Prospectus for its Capital Increase and Convertible Bond Issue Icon check
07/25/2023 ADOCIA announces Q2 2023 financial results and a €10 million financing operation Icon check
07/18/2023 ADOCIA confirms its eligibility for the PEA–PME Icon check
07/12/2023 Number of shares and voting rights of ADOCIA as of June 30th, 2023 Icon check
07/11/2023 EndoC-bH5 cells are storable and ready-to-use human pancreatic beta cells with physiological insulin secretion. Mol Metab. 2023 Jul 11;76:101772 Icon check
Webconference of July 6th, 2023
07/05/2023 ADOCIA Grants Sanofi an Exclusive Right to Negotiate a Partnership on M1Pram for 10 Million Euros and Obtains Commitment from Investors to Provide 10 Million Euros in Financing Icon check
06/23/2023 AdoShell® Islets, a new biomaterial for allogenic islet encapsulation, shows 6 months insulin secretion in diabetic immunocompetent rats, Dr. Ouardane Jouannot, June 23, 2023, 83rd scientific Sessions, ADA 2023
06/01/2023 Listing of ADOCIA shares suspended Icon check
05/15/2023 ADOCIA Announces the Appointment of Olivier Soula as Chief Executive Officer Icon check
04/30/2023 Number of shares and voting rights of ADOCIA as of April 30th, 2023 Icon check
04/27/2023 ADOCIA Announces the Release of its Universal Registration Document for the Year 2022 Icon check
04/25/2023 ADOCIA Reports Financial Results of First Quarter 2023 and Provides an Update on its Activities Icon check
04/20/2023 ADOCIA announces its annual Shareholders’ meeting to be held on May 11, 2023 in Paris Icon check
04/13/2023 Number of shares and voting rights of ADOCIA as of March 31st, 2023 Icon check
03/17/2023 Number of shares and voting rights of ADOCIA as of February 28th, 2023 Icon check
2022 Annual Results
03/15/2023 ADOCIA announces its annual results for 2022 and provides corporate and financial update Icon check
02/15/2023 Number of shares and voting rights of ADOCIA as of January 31st, 2023 Icon check
01/30/2023 ADOCIA – Letter to shareholders – January 2023 Icon check
01/30/2023 ADOCIA publishes its Letter to Shareholders Icon check
01/16/2023 Number of shares and voting rights of ADOCIA as of December 31st, 2022 Icon check
01/12/2023 ADOCIA Announces its financial calendar for 2023 Icon check
01/12/2023 A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes. Diabetes Obes Metab., 2023;25(5):1241-1248. Icon check
12/29/2022 ADOCIA Announces the Successful Phase 1 Study for BioChaperone® Lispro with Partner Tonghua Dongbao Icon check
12/21/2022 ADOCIA Announces its Participation at Upcoming Investor Conferences in January 2023 Icon check
12/15/2022 Number of shares and voting rights of ADOCIA as of November 30th, 2022 Icon check
12/01/2022 Adocia strengthens its cash position with EUR 6 million through the issuance of convertible bonds subscribed by European investors in order to accelerate the development of key products Icon check
11/16/2022 Number of shares and voting rights of ADOCIA as of October 31st, 2022 Icon check
10/25/2022 ADOCIA Reports its Cash Position and Revenue for the Third Quarter of 2022 and Provides Business Updates Icon check
10/13/2022 Number of shares and voting rights of ADOCIA as of September 30th, 2022 Icon check
10/06/2022 ADOCIA Announces Exceptional Weight Loss for Obese People with Type 1 Diabetes using M1Pram in a post-hoc analysis Icon check
10/03/2022 ADOCIA: Upcoming investor meetings Icon check
Investors Webinar of Sept 20th, 2022
09/19/2022 ADOCIA Announces First Half 2022 Financial Results and Provides a Business Update Icon check
09/15/2022 ADOCIA Will Release its 2022 Half-Year Results on September 19th and Hold a Webinar on September 20th Icon check
09/14/2022 Number of shares and voting rights of ADOCIA as of August 31st, 2022 Icon check
09/07/2022 ADOCIA Announces First Cell Therapy Preclinical Proof of Concept of AdoShell® Islets for the Treatment of Type 1 Diabetes Icon check
2022 AdoShell Islets Presentation
08/25/2022 Number of shares and voting rights of ADOCIA as of July 31st, 2022 Icon check
08/24/2022 ADOCIA Reports Cash and Revenue for the Second Quarter and Provides Corporate Update Icon check
07/11/2022 Number of shares and voting rights of ADOCIA as of June 30th, 2022 Icon check
06/23/2022 Adocia publishes its Letter to Shareholders Icon check
06/23/2022 ADOCIA – Letter to Shareholders – June 2022 Icon check
06/21/2022 ADOCIA announces M1Pram Phase 2 Trial Meets Primary Objective by Reducing Weight in Overweight People with Type 1 Diabetes Icon check
06/14/2022 Number of shares and voting rights of ADOCIA as of May 31st, 2022 Icon check
05/20/2022 ADOCIA Announces its annual Shareholders’ meeting to be held on June 28, 2022 in Paris Icon check
05/18/2022 ADOCIA Reports Financial Results of First Quarter 2022 and Provides Corporate Update Icon check
05/18/2022 ADOCIA Announces The First Subject Treated In BioChaperone® Combo Clinical Studies with Partner Tonghua Dongbao Icon check
Join our mailing list. Subscribe